BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/28/2020 1:45:46 AM | Browse: 830 | Download: 1569
 |
Received |
|
2020-05-26 22:26 |
|
Peer-Review Started |
|
2020-05-26 22:28 |
|
First Decision by Editorial Office Director |
|
2020-06-15 17:40 |
|
Return for Revision |
|
2020-06-15 17:40 |
|
Revised |
|
2020-08-20 17:37 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-09-07 10:15 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-09-08 00:50 |
|
Articles in Press |
|
2020-09-08 00:50 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-09-14 11:13 |
|
Publish the Manuscript Online |
|
2020-09-28 01:45 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Opinion Review |
| Article Title |
Role of monoclonal antibody drugs in the treatment of COVID-19
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Claudio Ucciferri, Jacopo Vecchiet and Katia Falasca |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Katia Falasca, MD, PhD, Associate Professor, Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University “G. d’Annunzio” Chieti-Pescara, Via dei Vestini, Chieti 66100, Italy. k.falasca@unich.it |
| Key Words |
Tocilizumab; Anakinra; Canakinumab; Ruxolitinib; Clazakizumab; Siltuximab |
| Core Tip |
Elevated inflammatory cytokines have been reported in patients with coronavirus disease 2019 (COVID-19). Evidence suggests that elevated cytokine levels and high levels in inflammatory markers are responsible for multi-organ damage in patients with COVID 19. Numerous randomized clinical trials are currently underway to explore the effectiveness of interleukin-1 blockers, interleukin-6 inhibitors. Or other strategies. For this reason it is necessary to make the point about using biopharmaceutical drugs in COVID 19. |
| Publish Date |
2020-09-28 01:45 |
| Citation |
Ucciferri C, Vecchiet J, Falasca K. Role of monoclonal antibody drugs in the treatment of COVID-19. World J Clin Cases 2020; 8(19): 4280-4285 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i19/4280.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i19.4280 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
